NCT06801015 - Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

March 31, 2028

Conditions

Obesity

Interventions

DRUG

Semaglutide

Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week

DRUG

Tirzepatide

Both interventions are approved by FDA for the treatment of obesity and are administered by subcutaneous injection once per week

DRUG

Placebo

Placebo administered by subcutaneous injection once per week.

Trial Locations (2)

RECRUITING

Mayo Clinic in Rochester, Rochester

RECRUITING

Mayo Clinic Rochester, Rochester